
CLAIMS

1. A synergistic combination comprising at least one Gabapentinoid selected from the group consisting of Gabapentin and Pregabalin or a pharmaceutically acceptable salt, stereoisomer or solvate thereof, and at least one Sigma ligand of general formula (I)



(I)

wherein,

R_1 is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, and -COR_8;

R_2 is selected from the group consisting of hydrogen and substituted or unsubstituted alkyl;

R_3 and **R_4** together with the phenyl group form a naphthyl ring system;

R_5 and **R_6** together form, with the nitrogen atom to which they are attached, a morpholine-4-yl group;

n is selected from 2, 3 and 4;

R_8 is selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted, aromatic or non-aromatic heterocyclyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryloxy, and halogen,

or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof.

2. The synergistic combination according to claim 1, wherein the combination comprises 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof.

3. The synergistic combination according to any one of the preceding claims, wherein the combination comprises 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride.

4. The synergistic combination according to any one of the preceding claims, wherein the combination comprises 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride and Pregabalin.

5. The synergistic combination according to any one of the preceding claims, wherein the combination comprises 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yloxy]ethyl}morpholine hydrochloride and Gabapentin.

6. The synergistic combination according to any one of the preceding claims for use as medicine.

7. The synergistic combination according to any one of the preceding claims for use in the prophylaxis and/or treatment of pain.

8. The synergistic combination according to any one of the preceding claims for use in the prophylaxis and/or treatment of pain by potentiating the analgesic effect of the Gabapentinoid.

9. The synergistic combination according to any one of the preceding claims for use in the prophylaxis and/or treatment of pain, wherein the pain is neuropathic pain.